Oxytocin is a promising candidate for the treatment of social-deficit disorders such as Autism Spectrum Disorder, but oxytocin cannot readily pass the blood-brain barrier. Moreover, oxytocin requires frequent dosing as it is rapidly metabolized in blood. We fabricated four polymeric nanoparticle formulations using poly(lactic-coglycolic acid) (PLGA) or bovine serum albumin (BSA) as the base material. In order to target them to the brain, we then conjugated the materials to either transferrin or rabies virus glycoprotein (RVG) as targeting ligands. The formulations were characterized in vitro for size, zeta potential, encapsulation efficiency, and release profiles. All formulations showed slightly negative charges and sizes ranging from 100 to 278 nm in diameter, with RVG-conjugated BSA nanoparticles exhibiting the smallest sizes. No formulation was found to be immunogenic or cytotoxic. The encapsulation efficiency was ≥75% for all nanoparticle formulations. Release studies demonstrated that BSA nanoparticle formulation exhibited a faster initial burst of release compared to PLGA particles, in addition to later sustained release. This initial burst release would be favorable for clinical dosing as therapeutic effects could be quickly established, especially in combination with additional sustained release to maintain the therapeutic effects. Our size and release profile data indicate that RVG-conjugated BSA nanoparticles are the most favorable formulation for brain delivery of oxytocin.
Introduction
Developing new treatments for central nervous system (CNS) diseases is a pressing public health concern (Misra et al., 2003; Broderick et al., 2009; Herrmann et al., 2011; Strecker and Schwarz, 2008; Cai et al., 2016) . To treat neurological diseases in the brain, one route of treatment is delivering beneficial therapies, such as neuropeptides, across the blood-brain barrier (BBB) and into the brain. Neuropeptides are small protein-like molecules that are commonly co-released with neurotransmitters to modulate neurotransmission. Neuropeptides vary in their size, the neuroanatomical distribution of their neurons of origin and their partnered neurotransmitters for co-release. They have shown particular promise as potential therapeutics for CNS disorders as observed in animal studies that demonstrate profound efficacy in treating a number of disease states. Although there are many neuropeptides with potential therapeutic benefits, one of particular interest is oxytocin (OT). OT is a nine-amino acid neuropeptide that is synthesized in the paraventricular and supraoptic nuclei of the hypothalamus. It is released into peripheral circulation by the posterior pituitary gland and also functions as a neurotransmitter throughout much of the mammalian brain (Carson et al., 2013) . Although traditionally recognized as being involved in uterine stimulation during parturition, OT's role as a brain neurotransmitter in the OT system has been linked to many social functions such as behavior, recognition, comfort, and altruism (Donaldson et al., 2008; Engelmann et al., 1996; Modi and Young, 2012) . This has led to considerable interest in the therapeutic use of OT for CNS disorders with social deficit components, including autism and Dravet syndrome.
Unfortunately, a fundamental obstacle for the development of OT as a CNS medication is that it 1) does not readily passively cross the BBB following exogenous administration and 2) its half-life in the blood is short, on the order of minutes. The BBB limits large or hydrophilic molecules from readily entering the brain. This limits the range of compounds and scaffolds available to medicinal chemistry programs in the development of new chemical entities for treating CNS disorders. One method to overcome the resistance of the BBB is surgical cannulation of the brain ventricles for widespread or region-specific brain delivery of large molecule compounds to treat CNS disorders in animal models. Some of these compounds include neurotrophins such as brainderived neurotropic factor (BDNF) (Nagahara et al., 2009; Dawbarn and Allen, 2003) , secretase inhibitors for Alzheimer's disease (O'Brien and Wong, 2011) , anti-inflammatory cytokines (Opal and DePalo, 2000; Walker and Lue, 2007) , and therapeutic plasmid DNA for neuronal stimulation or myelin recovery and remodeling (Blesch and Tuszynski, 2007; Sloane et al., 2009; Soderquist and Mahoney, 2010) . However, surgical cannulation is an invasive procedure to deliver these molecules. Alternatively, researchers have tried to utilize the mechanisms present in the BBB to deliver compounds to the brain without physical or surgical disruption of the barrier.
An attractive strategy for targeted delivery of drugs into the brain is endogenous active transport systems such as receptor-mediated transport (RMT) (Pulicherla and Verma, 2015) . RMT is a class of transport system that transports macromolecules such insulin and transferrin between the blood and the brain. Transferrin (Tf) has been widely studied and shown to be a promising molecular probe for targeted drug delivery to the brain through RMT as transferrin receptors are known to be expressed in the luminal membrane of capillary endothelium of the BBB (Gan and Feng, 2010; Pardridge, 2007; Gatter et al., 1983) . Tf is a single chain 80 kDa protein that facilitates the movement of iron between the blood and brain. Tf-bound iron from blood binds to the Tf receptor (TfR) expressed on the BBB. The TfR is expressed mostly on endothelial cells, intestinal cells, hepatocytes, and monocytes. Tf-conjugated drug delivery systems (nanoparticles, liposomes and micelles) can improve drug transport across the BBB since Tf-receptors (TfR) are overexpressed in brain capillary endothelium (Pang et al., 2011; Qian et al., 2002; Ulbrich et al., 2009; Wiley et al., 2013; Yan et al., 2013; Ying et al., 2010) . Previous studies have extensively examined the Transferrin (Tf) system as a mean of targeting drug formulations to the brain (Qian et al., 2002; Ulbrich et al., 2009; Broadwell et al., 1996; Pardridge, delivery. 2014) . Tf can be adsorbed on or conjugated to different polymers including PLGA, polyethyleneglycol, lipopolyplexes, polymer-based cyclodextrin, and gold nanoparticles (Li et al., 2003; Pan et al., 2008; Sahoo and Labhasetwar, 2005; Zhang et al., 2009) . Building enthusiasm for RMT, recent studies have also described a new brain targeting ligand called Rabies Virus Glycoprotein (RVG), which putatively binds to nicotinic cholinergic receptors on the BBB to engage brain uptake of drug formulations . Both Tf and RVG have been used previously to target therapeutic peptides to the brain, and are as such likely to be effective in the transport of neuropeptides into the brain. However, to the best of our knowledge, no previous studies have examined these ligands in the brain targeting of neuropeptides using nanoparticles.
Nanotechnology such as nanoparticles can be used to encapsulate our target neuropeptide and can be coated with Tf or RVG to utilize receptor-mediated transport, more specifically transcytosis to move the therapeutic across the BBB. Previous studies have used a variety of approaches for sustained delivery and brain targeting of drug formulations. Gan et al. developed a nanoparticulate system with transferrin conjugated on its surface as a molecular probe to deliver clinical Taxotere across the BBB; furthermore, they showed that transferrinconjugated nanoparticles were more successful than unconjugated nanoparticles at reaching the brain (Gan and Feng, 2010) . Molecules can be encapsulated within different polymers including PLGA, BSA, polyethyleneglycol, lipopolyplexes, polymer-based cyclodextrin, and gold nanoparticles (Li et al., 2003; Pan et al., 2008; Sahoo and Labhasetwar, 2005; Zhang et al., 2009) . Additionally, since size plays a role in brain penetrance, smaller nanoparticles (under 200 nm) can potentially increase the penetrance of our formulation through the BBB and into the brain. We focused our efforts on using PLGA and BSA for our nanoparticle polymers because they are biocompatible, biodegradable, and are approved by the US Food and Drug Administration (FDA) (Makadia and Siegel, 2011; Jalil and Nixon, 1990; Jain, 2000; Ma et al., 2016; Wang et al., 2016; Oettinger et al., 2007) . We also have experience and expertise working with these polymers. For example, we have previously used PLGA to develop nanoparticulate dosage forms to deliver the anti-cancer drug camptothecin to B16 cells in vitro (Tong et al., 2003) . Additionally, our previous studies in non-human primates have shown low levels of toxicity using BSA as the polymer for particulate drug delivery (Oettinger et al., 2007) . Furthermore, both PLGA and BSA nanoparticles have sustained release properties which can increase halflife of OT thereby decreasing the frequency of administration and increasing patient compliance. Our goal was to optimize a formulation that provides an initial burst release of the peptide to induce rapid symptom control followed by a sustained release for prolonged therapeutic effects.
In the present study, we designed two polymeric-based nanoparticle formulations in order to increase the brain penetrance and extend the duration of action of OT. After the optimization of the formulation, we determined the physical, physiochemical, and release properties of the formulations as well as their potential for undesirable immunogenic reactions and cytotoxicity. Also, we compared formulations composed of PLGA and BSA particles conjugated with Tf or RVG in order to select a formulation based on our criteria for a desired small particle size and optimal release profile. Of the four final formulations, we found that our OT-loaded BSA nanoparticles conjugated to RVG produced the smallest-sized particles and maintained our desired release profile of OT.
Materials and methods

Materials
PLGA lactide:glycolide (50:50), polyvinyl alcohol, dichloromethane, indocyanine green, transferrin (Tf), and benzalkonium chloride were purchased from Sigma Aldrich (Milwaukee, WI, USA). Bovine serum albumin (Fraction V), glutaraldehyde (25% in water) and acetone were purchased from Fischer Scientific (Pittsburgh, PA, USA). Rabies Virus Glycoprotein (RVG) was purchased from GenScript (Piscataway, NJ, USA). All the chemicals were of analytical grade and used as is without further modification.
Experimental design
The size of the nanoparticles affects the ability of the nanoparticles to cross the BBB (Saraiva et al., 2016) . Given the importance of nanoparticle size in brain targeting, particle size of the nanoparticles were monitored to ensure uniform size distribution of the formulation (Hornig et al., 2009) . Various formulation and process parameters including polymer concentration, ratio of antisolvent and solvent and pH of solvent can influence the size of the nanoparticles (Chorny et al., 2002) . We performed a full factorial design to optimize the parameters for the BSA nanoparticle formulation such as pH of the aqueous solution, polymer concentration, and antisolvent (acetone):solvent (water) ratio. All three variables were evaluated at three different levels using a full factorial design of experiments. Results of the experiments were analyzed using JMP® (SAS) software as previously demonstrated by our group (Kolluru et al., 2013; Chablani et al., 2012; Shastri et al., 2013; Kolluru and Gala, 2015) .
Preparation of nanoparticles
PLGA nanoparticles were prepared using a multiple emulsion solvent evaporation and lyophilization method. Briefly, 100 mg of PLGA and 20 μL of sorbitan monooleate were dissolved in 5 ml dichloromethane. 10 mg of OT was dissolved in 1 ml of deionized water. The water/oil emulsion was prepared by homogenization at 35,000 rpm for 1 min and also followed by probe sonication for 5 min with a 30 s pause after each minute. This primary emulsion was added to 10 ml of a 1% w/v polyvinyl alcohol solution and homogenized using the same method as described for primary emulsion in order to obtain the final water/oil/water (w/o/w) emulsion. The emulsion was kept under stirring conditions for 6 h to remove dichloromethane and the formulation was lyophilized and the dried particles were stored in glass vials at −20°C for future use.
BSA nanoparticles were prepared by a coacervation/nanoprecipitation method followed by lyophilization. Briefly, 270 mg of BSA and 27 mg of OT were dissolved in 10 ml of 10 mM NaCl at pH 9.3. Acetone was added drop wise at a speed of 1 ml/minute to the aqueous solution at a ratio of 2:1 with stirring at 800 rpm. After desolvation, the nanoparticle suspension was cross-linked for 30 min with 25% (w/v) glutaraldehyde in water (200 μL of glutaraldehyde for 1000 mg of BSA). Unused glutaraldehyde was neutralized with sodium bisulphite. Trehalose (2% w/v) was added as a cryoprotectant and the nanoparticle suspension was lyophilized as above.
Tf and RVG conjugation to peptide-loaded nanoparticles
Previous studies have used Tf and RVG as brain targeting ligands (Blesch and Tuszynski, 2007; Gan and Feng, 2010; Kim et al., 2013) using other formulation technologies and to carry therapeutics other than neuropeptides into the brain. We attempted to adopt these approaches for nanoparticle formulations of neuropeptides. Tf and RVG were conjugated to PLGA and BSA nanoparticles in two steps. The first step required activation of the carboxylic acid terminal groups using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and NHS (98%) followed by conjugating Tf or RVG in the nanoparticles. Briefly, 1 ml (1 mg/ml) of EDC and NHS (1 ml, 1 mg/ml) was added to 10 ml of nanoparticle suspension containing 40 mg of OT-loaded PLGA or BSA nanoparticles. Carboxylic acid groups at the periphery were converted to amine-reactive esters by stirring the PLGA with EDC and sulfo-NHS reaction mixture at room temperature for 4 h. The activated NPs were then dispersed in 1 ml of PBS, and Tf (1 ml, 1 mg/ml) or RVG (1 ml, 1 mg/ml) was added drop-wise to the mixture. The mixture was stirred at room temperature for 2 h and incubated at 4°C overnight or 12 h. Finally, the samples were washed and lyophilized using a Labconco freeze dryer (Labconco corporation, Missouri, USA). The four lead formulations were prepared as listed in Table 1 .
Particle size, zeta potential and surface morphology
To determine the size and zeta potential of our nanoparticle formulations, a 50 μL aliquot of the nanoparticle suspension was diluted with 1.5 ml distilled water. Malvern Zetasizer (Malvern Instruments Inc, Massachusetts, USA) was used to measure the particle size and zeta potential of the nanoparticles utilizing the principle of dynamic light scattering. The results reported are average values from triplicate runs of three independent experiments for each sample. To visualize surface morphology, microparticles were mounted onto metal stubs using double-sided adhesive tape. After being vacuum coated with a thin layer (100-150 A°) of gold, the nanoparticles were observed under 20 kV using a scanning electron microscope (Phenom World Pure Scanning electron microscope, AZ, USA) to examine the morphology of the nanoparticles.
Peptide encapsulation efficiency
To determine the encapsulation efficiency, a known amount of each nanoparticle suspension was centrifuged at a speed of 35,000 rpm. The supernatant was obtained and the amount of peptide in the supernatant was determined by an OT-specific enzyme linked immunosorbent assay (ELISA) (Oxytocin ELISA kit, Catalogue no: ADI-901-153A-0001, Lot no: 12041404E, Enzo life Sciences, NY 11735). This amount was subtracted from the total amount of peptide used for the formulation to determine the peptide encapsulation efficiency inside the nanoparticles.
Fourier Transform Infrared spectroscopy (FT-IR) to determine conjugation efficiency
The adsorption of Tf and RVG on the surface of PLGA and BSA nanoparticles was investigated using FT-IR spectroscopy in order to determine the conjugation efficiency. The FT-IR spectra were recorded using IRAffinity-1S Spectrometer (Shimadzu Corporation, Japan). FTIR spectra of transferrin and RVG coated PLGA and BSA nanoparticles were obtained in the range of 4000-600 cm −1
. Spectral output was recorded by the transmittance as a function of wave number.
Immunogenicity
The potential of the formulations to induce an immunogenic reaction was assessed by measuring the amount of nitrite released by dendritic cells (DC) in presence of nanoparticulate formulations. Murine dendritic cells (DC 2.4, Millipore Sigma) were grown and maintained in DMEM with glucose, L-glutamine, and 10% FBS. DC cells were passaged at 70% confluence. For the assay, cells were plated in a 96 well-plate at 15,000 cells/well. The treatments consisted of untreated cells (negative control), the 4T1 immunogenic breast cancer vaccine (positive control), blank particles, and peptide particles. The cells were pulsed with 300 µg blank nanoparticles (1 mg/ml stock suspension) or peptide nanoparticles (1 mg/ml stock suspension) using incomplete DMEM in a 96-well plate for 16 h (n = 3). After 16 h, the supernatant was collected and analyzed for nitric oxide concentration using the Greiss chemical method (Gala et al., 2016) . The Greiss reagent was prepared by mixing equal volumes of 1% sulfanilamide and 0.1% N-(1-napthylethyldiamine) solutions. 100 μL of the supernatant was transferred to a 96 well plate, to which 100 µL of Greiss reagent was added. The plate was incubated for 10 min and read at 540 nm to assess the color change using a microplate reader (Synergy H1; BIO-TEK Instruments, Winooski, VT). The concentration of nitrite was calculated for each well of cells using the standard curve of NaNO 2 (1 mM stock concentration in distilled water further diluted to the highest standard at 100 µM followed by serial dilutions to 1.56 µM).
Cytotoxicity
The cytotoxicity of blank and peptide loaded nanoparticles was assessed by the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Cell suspension equivalent to 10,000 cells/ well was plated in a 96-well cell culture plate, and complete DMEM medium was added to obtain a volume of 100 µL per well. Various concentrations of the nanoparticles ranging from 0.5 µg/mL to 1000 µg/mL were added to the plates in triplicates and incubated for specified time points (24 and 48 h). Cells alone (untreated) and benzalkonium chloride were used as negative and positive controls, respectively. 10 μL of MTT Reagent was added to each well, including controls followed by incubation at 37°C for 2 to 4 h. When the purple precipitate was clearly visible, 100 μL of detergent reagent was added to all wells, including positive and negative controls. Absorbance in each well was measured at 570 nm in a microtiter plate reader. The formation of a colored product quantified by measuring absorbance can be correlated to the percentage of living cells.
In vitro release
The release of OT from nanoparticles was studied in phosphate buffered saline (PBS, pH 7.4) and in 10% mice serum collected from Swiss-Webster mice by submandibular bleeding (Golde et al., 2005) . Briefly, 10 mg of nanoparticles were suspended in 1 ml of PBS or 10% mice serum and kept for continuous shaking (100 rpm). Two different temperatures were used, 4°C and 37°C. At each time point, the tube was centrifuged at 35,000 rpm for 15 min, a sample of the supernatant was removed, after which the removed sample volume was replenished with media. The supernatant (n = 3) was analyzed for the amount of peptide (OT) released using an OT ELISA as mentioned earlier.
Results
Particle size, zeta potential and surface morphology
In general, the smaller the size of the nanoparticles, the more amenable they are for active transport across the BBB (Saraiva et al., 2016; Etame et al., 2011; Hanada et al., 2014; Sonavane et al., 2008) . The mean diameter of PLGA nanoparticles measured by Malvern zetasizer ranged between 197.7 and 278.3 nm. PLGA-based particles were negatively charged ranging from −11.9 to −19.6 mV. The mean diameter of the BSA nanoparticles ranged from 100.1 to 197 nm in diameter. All the BSA nanoparticles were negatively charged ranging from −15.4 to -22.8 mV. The lowest particle size (approx. 100 nm) was obtained using a BSA formulation. Size distribution of RVG-conjugated OT-loaded BSA nanoparticles showed two peaks where intensity of the main peak was 99.24%. This may happen due to aggregation of some nanoparticles. As more than 99% particles were within a very narrow distribution range, it can be said that very few particles had aggregated. For Tf-conjugated OT-loaded BSA nanoparticles, the intensity of the main peak was 92.6%. For RVG-and TF-conjugated OT-loaded PLGA nanoparticles there was only one peak for each type of particles and the intensities of the peaks were 99.9% and 100% respectively. Fig. 1 shows representative data from the Zetasizer as well as the scanning electron microscope. As can be seen, the particle formulations exhibited an even spherical shape. Table 2 summarizes the sizes and zeta potentials of the various formulations that were assessed.
Optimization of formulation by full factorial design
Parameters that affects the particle size are rank ordered by analysis of the formulation design with JMP® (SAS) software. Significant parameters (p < 0.05) affecting particle size (in the order of importance) are interaction of BSA concentration and acetone: water ratio (p < 0.0005) pH of the aqueous solution (p < 0.0006), interaction of pH and acetone: water ratio (p < 0.0013), acetone: water ratio (p < 0.0053). The optimization is listed in Table 3 .
3.3. Transferrin (Tf) and Rabies Virus Glycoprotein (RVG) conjugation to peptide loaded nanoparticles Fig. 2 (A and B) shows the FT-IR spectra of Tf-and RVG-unconjugated and conjugated PLGA nanoparticles. Fig. 2 (A) 
Encapsulation efficiency
The encapsulation efficiency was determined before the conjugation of the nanoparticles to Tf and RVG. The amount of peptide in the supernatant was subtracted from the total amount of peptide used for the formulation to determine the peptide encapsulation efficiency inside the nanoparticles. The oxytocin peptide content of the PLGA nanoparticles was 81 ± 2.5% (w/w) and for BSA nanoparticles it was 75 ± 2.5% (w/w). Fig. 1 . Representative particle sizes and morphology of our nanoparticle formulations. (Left) Size distribution of PLGA nanoparticles conjugated to Tf or RVG, (Middle) size distribution of BSA nanoparticles conjugated to Tf or RVG, and (Right) scanning electron microscopy images of the BSA nanoparticles conjugated to Tf at a 3 μm resolution. The BSA nanoparticles conjugated to RVG were too small to image at a 3 μm resolution. Tf = Transferrin; RVG = Rabies Virus Glycoprotein; PLGA = poly(lactic-co-glycolic acid); BSA = Bovine serum albumin; OT = Oxytocin.
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Immunogenicity determination
Nitric oxide release is an important indicator of innate immune response (Zughaier et al., 2005; Bogdan et al., 2000) . This can be used to determine the potential of nanoparticle formulations to induce immunogenic reactions. Fig. 3 shows the effects of each formulation of oxytocin on nitric oxide release. Neither the blank nor the OT-loaded nanoparticles induced significant nitric oxide release demonstrating desirable non-immunogenicity. The level of nitric oxide release was compared to a positive control, 4T1 murine tumor antigen loaded microparticles which result in a large nitric oxide release and high immunogenicity.
Cell cytotoxicity
The cytotoxic effects of the four lead nanoparticle formulations (as mentioned in Table 1 at given concentrations are depicted in Fig. 4 . None of the formulations were cytotoxic within the tested concentration range (0.0625-1 mg/mL) after 48 h. The percent cell viability is expressed relative to negative controls of cells treated with DMEM medium only. Benzalkonium chloride, used as the positive control was cytotoxic, as demonstrated by 21.44% and 20.089% cell viability after 24 and 48 h, respectively.
In vitro release
The release of OT from PLGA nanoparticles in PBS was sustained over a period of 21 days (Fig. 5) . OT was released from PLGA nanoparticles in a sustained manner and 50% of peptide was released over a period of 10.8 days (Fig. 5) . The release of OT from BSA nanoparticles in PBS was sustained over a period of 18 days with 50% of OT released over a period of 9.8 days (Fig. 5) . In 10% serum at pH 7.4 OT is released from BSA nanoparticles in sustained fashion, with initial burst release of around 20% and 50% of OT released over a period of 3 days at both 4°C and 37°C. In order to get a clearer view of the burst release, we conducted a release study for 6 h with sampling interval of 30 min. At the end of 6 h 37.07% and 32.8% OT was released from BSA nanoparticles at 4°C and 37°C temperature, respectively (Fig. 6) . The release of OT from PLGA nanoparticles was very slow with only 5% release at the end of 6 h at both 4°C and 37°C (Fig. 6 ). These data show that BSA nanoparticles have a faster initial release profile than PLGA particles, and that temperature does not have a significant effect on the release profile over the first 6 h. Our goal was to find a release profile that provides an initial burst release of the peptide to induce rapid symptom control followed by a sustained release for prolonged therapeutic effects. Fig. 7 demonstrates that the RVG-conjugated BSA nanoparticles have a mixed burst release/sustained release profile, with approximately 35% release within the first 6 h, but 50% release not occurring until approximately 3 days in solution. In Figs. 5, 6 and 7, all points represent the mean ± SD, and any points without error bars indicate instances in which the SD is encompassed by the data point.
Discussion
The purpose of this study was to extensively characterize several nanoparticle-based formulations of OT that can potentially cross the BBB. Our goal was to find a release profile that provides an initial burst release of the peptide to induce rapid symptom control followed by a sustained release for prolonged therapeutic effects. We focused our efforts on using PLGA and BSA for our nanoparticle polymers. This is because they are biocompatible, biodegradable and approved by the US Food and Drug Administration (FDA) (Makadia and Siegel, 2011) . Also, we have experience and expertise working with these polymers. We focused our efforts on conjugating our particles to Tf and RVG as these are documented brain targeting ligands, which provided us with four lead formulations: Tf-PLGA, Tf-BSA, RVG-PLGA, and RVG-BSA. We formulated and extensively characterized these four formulations. We used two criteria to decide upon an optimal formulation. First, we sought the smallest possible formulation, and used a minimum criteria of a size under 200 nm. Second, we sought a release profile that provides an initial burst release of the peptide followed by a sustained release, as we believe that this is the optimal profile for therapeutic effects, as well as the optimal profile for in vivo testing. On both accounts, our data shows that BSA particles conjugated to RVG offer optimal properties.
Receptor-mediated transport (RMT) is an appealing strategy for delivering drugs to the brain (Pulicherla and Verma, 2015) . Transferrin and rabies virus glycoprotein (RVG) has been used in previous studies as brain targeting ligands. Transferrin receptors are known to be expressed in the luminal membrane of capillary endothelium of the BBB (Gan and Feng, 2010; Pardridge, 2007; Gatter et al., 1983) . RVG is a short peptide that can bind to nicotinic cholinergic receptors on the BBB and it has been employed as a targeting ligand to deliver small interfering RNA (siRNA) to the brain (Kumar et al., 2007; Son et al., 2011) . Another study used RVG tagged PEGylated cyclodextrin (CD)-based nanoparticle to deliver siRNA to the brain (Gooding et al., 2015) . Although BBB represents one of the most difficult biological barriers to Abbreviations include, Tf = Transferrin; RVG = Rabies Virus Glycoprotein; PLGA = poly(lactic-co-glycolic acid); BSA = Bovine serum albumin; OT = Oxytocin. Table 3 Parameters affecting particle size.
Parameters affecting particle size Significance
Interaction of BSA concentration and acetone: water ratio p < 0.001 pH of the aqueous solution p < 0.001 Interaction of pH and acetone: water ratio p < 0.001 Acetone: water ratio p < 0.005
Parameters that significantly affect the particle size as revealed by full factorial design of formulation variables for BSA nanoparticles.
cross in order to deliver therapeutic agents/drugs/peptides for treatment of neurological diseases (Pardridge, delivery. 2014,; Abbott et al., 2010; Ballabh et al., 2004) , these promising studies have created enthusiasm that feasible approaches are under development. If a reliable system for active transport into the brain could be developed, a broad range of compounds that have poor passive brain bioavailability would be allowed to readily penetrate the brain. This innovation would be a paradigm shift for CNS drug delivery. There are hundreds to thousands of compounds with potentially therapeutic use for CNS disorders that have been abandoned because of poor brain bioavailability. Some of these compounds include neurotrophins such as BDNF (Nagahara et al., 2009; Dawbarn and Allen, 2003) , secretase inhibitors for Alzheimer's disease (O'Brien and Wong, 2011), anti-inflammatory cytokines (Opal and DePalo, 2000; Walker and Lue, 2007) , and therapeutic plasmid DNA for neuronal stimulation or myelin recovery and remodeling (Blesch and Tuszynski, 2007; Sloane et al., 2009; Soderquist and Mahoney, 2010) . Neuropeptides such as neuropeptide Y, BDNF, orexin, and others show profound therapeutic promise in defined disease states such as epilepsy, substance-use disorders, and obesity. The size, shape, and charge of our particles are highly critical for delivering drugs across the BBB (Kulkarni and Feng, 2013) . Nanoparticles smaller than 500 nm are usually taken via the clathrin-mediated transport system whereas larger particles are usually transported via macropinocytosis (Kou et al., 2013) . In reference to charge, negatively-charged nanoparticles are endocytosed by interacting with the positively charged protein sites that flanks the membrane (Kou et al., 2013; Lerch-Bader et al., 2008; Yeung et al., 2008) . Previous studies report that negatively charged nanoparticles are highly endocytosed by cells due to their repulsive interactions with the negatively charged cell surface (Kou et al., 2013; Yeung et al., 2008) , and positively charged particles show substantially reduced BBB penetrance. Our nanoparticle formulations exhibit a smooth, regular and spherical shape, which helps maximize uptake, as spherical particles are efficiently taken up via both clathrin and caveolae mediated transport (Tan et al., 2013; Truong et al., 2015) . Particles below 200 nm are desirable to maximize the probability of efficient brain uptake. In initial studies, we have generated PLGA particles conjugated to Tf using homogenization. However, the particles size exceeded 200 nm with this approach. We modified the production method to sonication and were able to readily achieve particles sizes below 200 nm. Such sizes were also readily achievable with BSA nanoparticles. However, it is important to note the BSA particles conjugated to RVG clearly achieved the smallest particles sizes.
In order to demonstrate the therapeutic viability of our nanoparticulate formulations, we have completed both immunogenicity and cytotoxicity studies in vitro. As confirmed in our past research, our nanoparticle formulations have shown to be both safe and non-toxic in Fig. 3 . Induction of nitric oxide release by our lead oxytocin formulations. The oxytocin formulation was generated by double emulsion solvent evaporation by sonication. All points represent the mean ± standard error. Abscissae: Various formulations compared to the negative control of untreated cells and the positive control of the 4T1 breast cancer vaccine that induces a robust immune response. Ordinates: Measured concentration of nitric oxide expressed on an absolute scale in units of micromolar. All experiments were conducted in triplicate. Fig. 4 . Cytotoxicity profile of the nanoparticle formulations. After 48 h of exposure, none of the four formulations were cytotoxic across the tested concentration range (0.0625-1 mg/mL). As there were no differences between the concentrations tested, only the highest concentration (1 mg/mL) is shown. Abscissae: Various formulations compared to the negative control of untreated cells and the positive control of benzalkonium chloride (a cationic surfactant that has biocidal activity). Ordinates: Cell viability expressed as a percentage of the negative control at 6 h. All experiments were conducted in triplicate. Fig. 5 . Release of OT from PLGA and BSA nanoparticles in PBS, pH 7.4. The release of OT from PLGA nanoparticles was sustained over a period of 21 days. OT was released from PLGA nanoparticles in sustained fashion with 50% of the OT released over a period of 10.8 days. The release of OT from BSA nanoparticles was sustained over a period of 18 days and 50% of OT was released over a period of 9.8 days. Abscissae: Day following addition of the formulation to solution. Ordinates: Measured concentration of free oxytocin in solution expressed as a percentage of the maximally measured release. All points represent the mean ± SD, and any points without error bars indicate instances in which the SD is encompassed by the data point. PLGA = poly(lactic-co-glycolic acid); BSA = Bovine serum albumin; OT = Oxytocin. Fig. 6 . Release OT from PLGA (prepared by sonication) and BSA nanoparticles in 10% serum, pH 7.4 over 6 h at 4°C and 37°C. At the end of 6 h, 37.07% and 32.8% of the OT has been released from the BSA nanoparticles at 4°C and 37°C temperature, respectively. In contrast, only 5% of the OT had been released from the PLGA nanoparticles at either temperature. Abscissae: Hour following addition of the formulation to solution. Ordinates: Measured concentration of free oxytocin in solution expressed as a percentage of the maximally measured release. All points represent the mean ± SD, and any points without error bars indicate instances in which the SD is encompassed by the data point. PLGA = poly(lactic-co-glycolic acid); BSA = Bovine serum albumin; OT = Oxytocin.
non-human primates. In primates, all parameters related to liver toxicity (such as SGOT, SGPT) and kidney toxicity (such as serum creatinine, serum bilirubin) were normal after repeated nanoparticulate administrations when compared to the control group. Also, no antibody titers in response to our polymeric particle matrix were detected demonstrating the absence of an immune response to the polymer matrix formulation (Oettinger et al., 2007) . For confirmation of a potential innate inflammatory response, nitric oxide assays are an important tool. We have demonstrated that there is no significant difference in the amount of nitric oxide released in the supernatant of cells exposed to peptide-loaded nanoparticles compared to blank nanoparticles or the cells alone. This indicates minimal if not negligible immunogenicity of our formulation. For reference, nitric oxide release in response to our OT-loaded particles was substantially lower compared to cells that were exposed to a well-known highly-immunogenic breast cancer vaccine formulation. Likewise, cytotoxicity of blank nanoparticles was assessed by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay in a macrophage (RAW 246.7) cell line. We found no significant cell death following 48 h of exposure to our formulations indicating that our formulation was not significantly toxic to the cells.
A major advantage of a nanoparticle formulation for peptide delivery is that the encapsulation protects the peptide from degradation, and sustains the delivery of the therapeutic agent over an extended period of time (Mudshinge et al., 2011) . This sustained delivery allows for fewer administrations and easier compliance, an issue of particular importance in the treatment of chronic substance abuse disorders or in patients that have difficulty with compliance. Resultantly, the OT can provide long-lasting therapeutic effects in the brain, improving the health of those suffering with various cognitive ailments. We have demonstrated that our formulations maintain a sustained release profile of OT in vitro in both PBS and plasma, which was confirmed using ELISA (Figs. 5 and 7). During our release studies, we took samples in 30-minute interval initially, then hourly, and then daily to establish a release profile covering several weeks. In order to select the most viable formulation to test in vivo, we explored the two factors discussed prior 1) size and 2) suitable sustained release criteria. We found that the RVG-conjugated BSA nanoparticles were smaller than our PLGA particles or Tf-conjugated BSA particles. The rank order of size of our nanoparticulate formulations was as follows: RVG-conjugated BSA (100.1 nm), Tf-conjugated BSA (196.3 nm), Tf-conjugated PLGA (191.7 nm), RVG-conjugated PLGA (201.2 nm). For the purpose of our treatment with OT, we desired an initial burst release followed by a sustained for several days. The OT release in 6 h at 37°C serum was as follows: BSA nanoparticles (32.8% release), and PLGA nanoparticles (5% release). Hence, we determined that our PLGA nanoparticle formulations would not be viable candidates since they released OT very slowly compared to BSA particles thereby reducing the therapeutic window for OT in the brain. Therefore, when selecting the final formulation to test in vivo, we determined that our BSA nanoparticles conjugated to RVG formulation was the most suitable candidate. Although the two BSA-based formulations demonstrated desirable release profiles, the RVG-conjugated BSA nanoparticles were almost half the size of Tf-conjugated BSA nanoparticles. Hence when taking into account size and the OT-release profile, we concluded that RVG-conjugated BSA nanoparticles would be the most appropriate formulation to move forward with in our in vivo murine models.
Conclusion
In this study, biodegradable Tf or RVG-conjugated PLGA and BSA nanoparticles loaded with oxytocin were successfully prepared by solvent evaporation and nanoprecipitation/coacervation methods respectively. Our formulations were also characterized using various methods such as zeta sizing and scanning electron microscopy. Significant parameters affecting particle size were ranked and optimized to produce the final desirable formulations for future proposed in vivo testing. We found that our nanoparticles were uniformly distributed in nm range, spherically shaped, and individually dispersed. We also found that the nanoparticles formulations were non-immunogenic and nontoxic. All four formulations showed sustained the delivery of the therapeutic agent allowing for fewer administrations and easier compliance. Therefore, our nanoparticulate formulation could serve as a potential candidate for delivering drugs and therapeutic peptides across the BBB non-invasively. Among the four formulations, the OT-loaded BSA nanoparticles conjugated to RVG formulation produced particles that were the smallest in size and demonstrated a desirable release profile, advocating it as a very strong candidate for drug delivery to the brain. We further propose testing our selected nanoparticle formulation in vivo in well-characterized murine disease models. Fig. 7 . Release OT from BSA nanoparticles in 10% serum, pH 7.4 at 4°C. 50% of the OT was released over a period of 3 days. Abscissae: Day following addition of the formulation to solution. Ordinates: Measured concentration of free oxytocin in solution expressed as a percentage of the maximally measured release. All points represent the mean ± SD, and any points without error bars indicate instances in which the SD is encompassed by the data point. BSA = Bovine serum albumin; OT = Oxytocin.
